Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $46.3 million.

  • Spyre Therapeutics' Total Current Liabilities fell 1957.8% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 1957.8%. This contributed to the annual value of $54.1 million for FY2024, which is 6905.37% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Total Current Liabilities is $46.3 million, which was down 1957.8% from $83.1 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Total Current Liabilities ranged from a high of $232.2 million in Q2 2023 and a low of $12.6 million during Q1 2023
  • Over the past 5 years, Spyre Therapeutics' median Total Current Liabilities value was $32.0 million (recorded in 2023), while the average stood at $45.1 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Total Current Liabilities soared by 136409.03% in 2023, and later crashed by 9047.43% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Total Current Liabilities stood at $20.1 million in 2021, then decreased by 27.24% to $14.7 million in 2022, then soared by 118.19% to $32.0 million in 2023, then surged by 69.05% to $54.1 million in 2024, then decreased by 14.4% to $46.3 million in 2025.
  • Its Total Current Liabilities stands at $46.3 million for Q3 2025, versus $83.1 million for Q2 2025 and $70.7 million for Q1 2025.